TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has received the US$3 million Tranche B advance from Vantive US Healthcare LLC (“Vantive”) pursuant to the previously disclosed senior secured promissory note entered into in May 2025.
Related Questions
How will the $3 million tranche from Vantive affect Spectral Medical’s cash runway and upcoming financing requirements?
What are the specific terms and covenants of the senior secured promissory note, and could they lead to dilution or restrictions for shareholders?
How does this funding round compare to financing activities of peer theranostic or sepsis-focused companies, and what impact might it have on the stock’s valuation relative to peers?